The single best way to protect against influenza is to get vaccinated. During the 2015-2016 flu season, the estimated number of illnesses prevented by the flu shot was 5.1 million. Also, in April of this year, a study published in Pediatrics was the first of its kind to prove the influenza vaccine reduced the risk of influenza-associated death in children ages six months through 17 years. Influenza is a serious disease and taking measures to prevent it should be a priority.
In the wake of Hurricanes Harvey and Irma, the U.S. Food and Drug Administration (FDA) and Centers for Medicare and Medicaid Services (CMS) are reminding people to take extra precautions when it comes to prescription drugs and medical equipment.
The federal Food and Drug Administration (FDA) has taken what it describes as “historic action,” approving what it calls the first gene therapy in the United States. It is the first chimeric antigen receptor T cell (CAR-T) therapy to receive FDA approval.
The action offers hope for young patients with a form of acute lymphoblastic leukemia (ALL) just before September, which is Blood Cancer Awareness Month. ALL, a form of blood and bone marrow cancer, is the most common type of cancer in children. As the first immunotherapy based on CAR-T for cancer to be approved, it also offers hope for immune-oncology researchers and pharmaceutical manufacturers.
There is no consistent industry definition of “specialty drugs,” but they are usually high-cost, large-molecule biologic products that are often injected to treat genetic conditions or mutations. Specialty drugs frequently target what are referred to as rare diseases and ultra-rare diseases, or orphan and ultra-orphan diseases.In the United States, a disease is considered rare if it affects less than 200,000 people, and generally if it affects fewer than 10,000 people it is described as “ultra-rare.” There are an estimated 7,000 rare diseases and disorders, affecting a combined total of more than 30 million people in the U.S. This recognition has helped shape the research and development agenda of pharmaceutical manufacturers.
Opioid addiction is a national epidemic, a crisis so significant that the White House has declared it a national emergency.